Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
about
Human polyomavirus reactivation: disease pathogenesis and treatment approachesMultiple Sclerosis: Where Will We Be in 2020?Natalizumab for relapsing remitting multiple sclerosisNatalizumab for induction of remission in Crohn's diseaseNatalizumab for induction of remission in Crohn's diseaseIdentification of targets and new developments in the treatment of multiple sclerosis--focus on cladribineCMX001 (1-O-hexadecyloxypropyl-cidofovir) inhibits polyomavirus JC replication in human brain progenitor-derived astrocytesMolecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brainIdentification of a third human polyomavirusNatalizumab: A new treatment for relapsing remitting multiple sclerosisEvaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathyCurrent stage in inflammatory bowel disease: What is next?Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated EntitiesTreatment-related progressive multifocal leukoencephalopathy: current understanding and future stepsThe importance of mouse models to define immunovirologic determinants of progressive multifocal leukoencephalopathyBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewInflammatory pathways of importance for management of inflammatory bowel diseaseAn update on the use of natalizumab in the treatment of multiple sclerosis: appropriate patient selection and special considerationsDesign of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarateProgressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapiesDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabRisk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisMonoclonal antibodies and progressive multifocal leukoencephalopathyNatalizumab and the role of alpha 4-integrin antagonism in the treatment of multiple sclerosisThe blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targetingRisk of Biologic Therapy-Associated Progressive Multifocal Leukoencephalopathy: Use of the JC Virus Antibody Assay in the Treatment of Moderate-to-Severe Crohn's DiseaseA novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory diseaseFunctional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disordersThe long and evolving relationship between viruses and multiple sclerosisNeutrophils and immunity: challenges and opportunitiesProgressive multi-focal leucoencephalopathy - driven from rarity to clinical mainstream by iatrogenic immunodeficiency.Progressive Multifocal Leukoencephalopathy in HIV-Uninfected Individuals.Clinical Trials in Neurovirology: Successes, Challenges, and PitfallsProgressive multifocal leukoencephalopathy: lessons from AIDS and natalizumab.Medical management of Crohn's disease: current therapy and recent advances.Diagnostic biomarkers in multiple sclerosis.PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section.Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.Therapeutic interference with leukocyte recirculation in multiple sclerosis.Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases.
P2860
Q21285083-C9120413-5478-407E-BA80-010ADD3C4D5BQ22252863-C1520704-58B2-4EC5-8C9B-78AD645E38A0Q24235861-4BD06D24-1B52-40BB-9919-9B5B6859F5BBQ24245190-DCB54964-6276-4C9D-A7C3-CBA742C7F487Q24246262-95A21D31-C597-42D2-AFB5-D50A1EA3C25FQ24597369-0BEFD35E-B1FB-4953-80C8-40A46EC2E42FQ24599841-14ED2A3F-AF44-4178-BD6A-3D1EA0A8C220Q24619923-CF4DC2A9-8C81-4372-8F68-DAC7AFB16087Q24672044-1070CC22-A037-420E-B68E-EFD437255FDAQ24683014-A96F18E5-4F59-476D-9A03-D9B6E92E5EE1Q24683776-510750A2-4F1B-4C69-A3B1-26C6645FA277Q26777429-3200BAC5-AFCC-4044-83E3-E1C42AC43A5FQ26781389-3277AE07-EB51-4D3A-B6E0-604E3DD6541BQ26823444-878D614D-AF9F-48BF-827A-B81E58EEF538Q26859307-17AA4A1E-7C1E-429F-9FC1-FA5869AE3D0CQ26999417-1A3E7E83-29DC-4246-8C3A-559AA9592DF3Q27005445-A80275E1-5EEB-4FE9-8B79-55B66E86BA3FQ27009769-CDB3A211-BB09-4E8A-B422-D7D4FF093043Q27021147-C7405294-77B7-413C-8466-BF5D38FE01A7Q27028025-58197862-E0CD-4C46-AA97-5048CE88CFAFQ28083872-9120B2F4-DA9B-42B3-9C55-B2DF54E21C6FQ28087414-93B085E1-1FA5-4EA0-80FE-EAE570E3F3B6Q28270413-63264435-FBF8-4359-8089-A799BB891556Q28277470-2723A7EB-B1BB-4B0C-AFAC-03D2D9E1DB27Q28299076-A509EC25-B318-443C-9B9B-BB05DD91AF9BQ28538974-BD0B0F00-3171-4CB2-A8A5-F81A190849AEQ28542368-D36DE2EF-F089-442E-B58A-AA6911A6CFCDQ28740884-15B489EE-3A13-40AB-82BB-76ED74533246Q29301310-F52DE5BB-58FA-4C58-ADE5-DC6619F444B0Q29617616-5CCBB95A-FE2A-4EE0-9535-39988EA57609Q30235523-6852FA7A-4ACA-4D59-9065-FED1331E7DC3Q30245002-1989AE95-6674-41AF-B260-CCCBF78BE666Q30250271-0CEF76B1-86AB-448C-A524-AAF1C083473AQ30354301-C025E116-017E-4FC2-BE22-BA62C7A9230FQ30450875-DB0B97F8-2696-4C63-BCFA-F6761C63EF06Q30598338-3BBA3363-4BEA-40D6-88AC-8494728AE568Q30613846-16F17773-01DF-4649-A98D-3D140EBE623EQ30815289-1B0246B5-E586-4F14-9014-945C3E2D2126Q30884219-4281C3BB-7CED-40F6-95A6-E81006D2015FQ30902172-8198D6AA-4898-4756-BAA0-A374A8719D10
P2860
Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
description
2005 nî lūn-bûn
@nan
2005 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@ast
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@en
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@nl
type
label
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@ast
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@en
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@nl
prefLabel
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@ast
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@en
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@nl
P3181
P356
P1476
Progressive multifocal leukoen ...... beta-1a for multiple sclerosis
@en
P2093
B K Kleinschmidt-DeMasters
P304
P3181
P356
10.1056/NEJMOA051782
P407
P577
2005-06-09T00:00:00Z